Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jazz Pharmaceuticals and Azur Pharma have agreed to combine their businesses to form Jazz Pharmaceuticals plc in Ireland.
Subscribe to our email newsletter
The combined company is expected to have a diversified revenue base from 12 products currently marketed in the US in the CNS and women’s health areas.
Following the merger, shareholders of Jazz would own slightly under 80% of Jazz Pharmaceuticals plc, and Azur Pharma shareholders would own slightly over 20%.
Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, would be chairman and CEO of Jazz Pharmaceuticals plc.
Jazz chairman and CEO Bruce Cozadd said their combined organizations would have a diverse portfolio of products and an international platform, paving the way for long term growth that builds on their current strengths.